+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of NMDAR1 expression in mouse brain lysate.    

  
  

The N-methyl-D-aspartate receptor 1 (NMDAR1) antibody is associated with autoimmune encephalitis, particularly anti-NMDAR encephalitis, first identified in 2007. NMDAR1. a critical subunit of NMDA receptors, mediates synaptic plasticity, learning, and memory. Autoantibodies targeting the GluN1 subunit disrupt receptor function, leading to excitatory neurotransmission imbalance. This condition often manifests with neuropsychiatric symptoms, including psychosis, seizures, memory deficits, and autonomic instability.

Anti-NMDAR encephalitis is frequently linked to ovarian teratomas but may also arise post-infection or idiopathically. Diagnosis relies on detecting IgG antibodies in cerebrospinal fluid or serum via cell-based assays. Early recognition is crucial, as prompt immunotherapy (corticosteroids, IVIG, plasma exchange) and tumor removal (if present) improve outcomes.

Research highlights broader implications: NMDAR1 antibodies are occasionally detected in schizophrenia, epilepsy, or neurodegenerative disorders, though their pathogenic role remains debated. Experimental models show antibody-induced receptor internalization and reversible synaptic density loss, supporting direct neurotoxicity. Ongoing studies aim to clarify antigenic epitopes, genetic predispositions, and long-term neurological effects, emphasizing their clinical and mechanistic relevance in autoimmune and neuropsychiatric diseases.